广州达安基因股份有限公司投资者关系活动记录表 证券代码：002030 证券简称：达安基因 | | 调研公司经营和产品的情况（以调研机构提问，公司高管回答 | | --- | --- | | | 的方式展开） | | | 问题一：目前从整个行业上来说，我们公司的优势是什么？ | | | 答：各级医院、第三方实验室和经销商伙伴始终是公司最核心 | | | 的资产。公司对头部三甲医院的客户保有率保持较高水平。基 | | | 于这一优质客户基础，公司一方面在巩固传统优势领域的同 | | | 时，积极拓展科研、疾控等新市场；另一方面，持续优化产品 | | | 结构，推动从分子诊断向体外诊断全领域的布局，并推出如 | | | HIV DNA检测等高附加值检测项目。另外，当行业竞争加剧， | | | 缺乏核心竞争力和成本控制能力的企业会慢慢被淘汰，目前行 | | | 业还在深度调整期，从客户保有、资产质量、研发实力等因素 | | | 来看，公司穿越行业周期的基本盘依然很扎实。 | | | 问题二：未来公司是否考虑兼并购的方式来扩大公司规模？ | | | 答：公司聚焦IVD领域发展前沿，研判并捕捉产业链上下游的 | | 投资 ...

Group 1: Financial Performance - The company's revenue in the first half of the year decreased by 15.44% compared to the same period last year, primarily due to changes in industry demand and adjustments in procurement prices [2][3] - The company's cash funds decreased by 47.18% since the beginning of the year, attributed to an increase in cash management limits for idle funds, which will not affect normal operations or future investment plans [3][4] - As of June 30, 2025, revenue from the South China region accounted for 45%, while revenue from outside South China accounted for 55% [4] Group 2: Strategic Plans and Market Expansion - The company is open to mergers and acquisitions that can create synergies with existing operations and extend the industrial chain, supported by the establishment of a strategic planning department [3][4] - Future market expansion will focus on enhancing the marketing system and exploring overseas markets to increase overall market share [4][5] - The company plans to deepen its marketing system and focus on new product development to stabilize market size amid declining sales of certain products [7][8] Group 3: Research and Development - R&D expenses decreased year-on-year but accounted for approximately 38% of the company's revenue, reflecting a commitment to research despite the decline [6][7] - The company emphasizes innovation in product development, with new products typically taking 3-5 years from initiation to certification [4][6] - A dynamic review mechanism for ongoing projects will be implemented to adjust R&D efforts based on market dynamics and end-user needs [4][8] Group 4: Competitive Strategy - The company maintains a multi-diagnostic technology platform, focusing on infectious diseases, precision medicine, and public health, to enhance service quality and market competitiveness [5][7] - Challenges in overseas markets include geopolitical policies and competition, with the company primarily serving clients in Latin America and Southeast Asia [6][7] - The company aims to improve operational efficiency through strategic adjustments and cost reduction measures in response to industry policies and market demands [7][8]

Core Points - The company held its third extraordinary general meeting of shareholders on September 15, 2025, with no resolutions being rejected [1][2] - The meeting was conducted through a combination of on-site and online voting [3] Meeting Details - The meeting took place at 14:30 on September 15, 2025, at the company's lecture hall in Guangzhou [4][5] - A total of 723 shareholders and their authorized representatives attended, representing 461,356,913 shares, which is 32.8732% of the total shares [6][22] - The meeting was legally compliant with relevant laws and regulations [5][20] Voting Results - The following resolutions were passed: 1. Amendment to the Articles of Association: Approved by 450,940,523 shares (97.7422% of votes) [9][26] 2. Revision of Board Meeting Rules: Approved by 451,794,639 shares (97.9274% of votes) [10][27] 3. Revision of Shareholder Meeting Rules: Approved by 451,805,532 shares (97.9297% of votes) [11][28] - The voting results indicate a significant majority in favor of the proposed amendments, with a notable dissent from minority investors on some resolutions [9][10][11] Legal Opinion - The legal opinion provided by the law firm confirmed that the meeting's procedures, participant qualifications, and voting processes were in accordance with the law [13][30]

证券代码：002030 证券简称：达安基因 公告编号：2025-050 3、本次股东会以现场投票与网络投票相结合的方式召开。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间： 广州达安基因股份有限公司 2025 年第三次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决议案的情形。 2、本次股东会未涉及变更前次股东会决议。 （1）现场会议召开时间：2025 年 9 月 15 日下午 14:30 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 9 月 15 日上午 9:15—9:25，9:30—11:30 和下午 13:00—15:00；通过深圳 证券交易所互联网投票系统投票的时间为 2025 年 9 月 15 日上午 9:15 至 2025 年 9 月 15 日下午 15:00 期间的任意时间。 2、会议召开地点：广州市高新技术开发区科学城香山路 19 号公司一楼讲学 厅 3、会议召开方式：现场投票与网络投票相结合的方式 4、会议召集人：公司董事会 5、会议主 ...

1. 经公司 2024 年第三次临时股东会审议通过的《公司章程》； 2. 公司 2025 年 8 月 30 日刊登于《证券时报》《上海证券报》《经济参 考报》、巨潮资讯网（www.cninfo.com.cn）及深圳证券交易所网站的 《广州达安基因股份有限公司第九届董事会第一次会议决议公告》； 3. 公司于 2025 年 8 月 30 日刊登于《证券时报》《上海证券报》《经济 参考报》、巨潮资讯网（www.cninfo.com.cn）及深圳证券交易所网站 的《广州达安基因股份有限公司第八届监事会第七次会议决议公告》； 4. 公司 2025 年 8 月 30 日刊登于《证券时报》《上海证券报》《经济参 考报》、巨潮资讯网（www.cninfo.com.cn）及深圳证券交易所网站的 《广州达安基因股份有限公司关于召开 2025 年第三次临时股东会通知 的公告》（以下简称《股东会通知》）； 5. 本次股东会股权登记日（2025 年 9 月 9 日）的股东名册； 6. 出席现场会议的股东的到会登记记录及凭证资料； 北京市金杜（广州）律师事务所 关于广州达安基因股份有限公司 2025 年第三次临时股东会的法律意见书 致： ...

Group 1 - The company, Da An Gene, announced that it has recently obtained a medical device registration certificate issued by the National Medical Products Administration [2]

格隆汇9月8日丨达安基因(002030.SZ)公布，公司取得国家药品监督管理局颁发的医疗器械注册证一 个，具体为：医疗器械名称：人类免疫缺陷病毒1型（HIV-1）DNA检测试剂盒（PCR-荧光探针法）， 注册证编号：国械注准20253401805。有效期自批准之日起至2030年9月4日。预期用途：本产品用于体 外定性检测人全血样本中的人类免疫缺陷病毒1型脱氧核糖核酸（HIV-1DNA）（仅M组）。 ...

Group 1 - The company, DaAn Gene (002030.SZ), has recently obtained a medical device registration certificate from the National Medical Products Administration [1] - The registered product is an HIV-1 DNA test kit (PCR fluorescent probe method), with the registration number: Guo Xie Zhu Zheng 20253401805 [1] - The certificate is valid from the date of approval until September 4, 2030, and the product is intended for in vitro qualitative detection of HIV-1 DNA in human whole blood samples [1]

Core Viewpoint - The company, Da An Gene, has recently obtained a medical device registration certificate from the National Medical Products Administration for an HIV-1 DNA testing kit, indicating a significant advancement in its product offerings [1]. Group 1 - The medical device registration certificate is specifically for the Human Immunodeficiency Virus Type 1 (HIV-1) DNA testing kit using PCR fluorescent probe method [1]. - The registration certificate number is 国械注准20253401805, and it is valid from the date of approval until September 4, 2030 [1]. - The expected use of this product is for the qualitative detection of HIV-1 DNA in human blood samples, specifically targeting the M group [1].

转自：证券时报 人民财讯9月8日电，达安基因(002030)9月8日晚间公告，近日公司取得国家药品监督管理局颁发的医疗 器械注册证一个，医疗器械名称为人类免疫缺陷病毒1型（HIV-1）DNA检测试剂盒（PCR荧光探针 法），预期用途为本产品用于体外定性检测人全血样本中的人类免疫缺陷病毒1型脱氧核糖核酸（HIV- 1DNA）（仅M组）。 ...